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Abstract
One of the most controversial ethical issues in genomics research is the return of individual 
research results to research subjects. As new technologies, including whole-genome sequencing, 
provide an increased opportunity for researchers to find clinically relevant research results, the 
questions related to if, when and how individual research results should be returned become more 
central to the ethical conduct of genomic research. In the absence of federal guidance on this issue, 
many groups and individuals have developed recommendations and suggestions to address these 
questions. Most of these recommendations have focused on the return of individual results from 
disease susceptibility studies. However, in addition to predicting the development of disease, 
genomic research also includes predicting an individual’s response to drugs, especially the risk of 
developing adverse events. This article evaluates and compares the return of individual research 
results from disease susceptibility studies versus pharmacogenomic studies.
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Setting the stage
One of the most challenging ethical issues in genomic research is the return of individual 
research results (ROR) to research subjects. The NIH data-sharing policy for genome-wide 
association studies, suggests that “contributing institutions and institutional review boards 
(IRBs) may want to establish policies to determine when it is appropriate to return 
individual findings from research studies” [101]; however, the content of such policies is left 
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to the individual institution. In the absence of national guidance, recommendations from 
individuals and groups have flourished to address if, when, under what conditions and how 
individual genomic research results should be shared with research participants [1–6,102]. 
Most of these efforts have focused on the return of research results that have implications for 
the susceptibility of developing a future disease. However, genomic researchers study not 
only the prediction of disease, but also individual responses to treatment. The goal of 
pharmacogenomics (PGx) research is to evaluate genetic variations in an individual’s 
genome to predict how a patient may respond to a particular therapy or dose, including 
predicting toxicity and effectiveness [7]. PGx research is the most promising area of 
genomic research that has a direct application in clinical practice today, which lends urgency 
to addressing the ROR issues it raises [7]. Furthermore, cancer genomic researchers have 
indicated that one of the most frequent types of clinically relevant research results being 
found is related to PGx [8].
Consider the following scenario: you are conducting a genome-wide association study in 
women with breast cancer, analyzing peripheral neuropathy following treatment with 
doxorubicin. Your population is young (<45 years old), newly diagnosed patients 
undergoing their initial treatment. You discover that three patients demonstrate multiple 
variations that, in previous retrospective studies, were each associated with severe, often 
permanent neuropathy. What is your responsibility to communicate this finding to some 
oversight or advisory committee? What are the risks and benefits of returning the finding to 
the patient and/or their treating physician? In the same study, you also discover that three 
different women show a gene variation that, in previous retrospective studies, was 
associated with development of non-small-cell lung cancer. Although this is an incidental 
finding, unrelated to your study aims, what is your responsibility to communicate this 
finding to some oversight or advisory committee? What are the risks and benefits associated 
with communicating this finding to the research subject?
The issue of return of individual research results is challenging because providing 
individuals with clinically significant personal information crosses the boundaries that are 
supposed to distinguish research from clinical practice [2,9,10]. A central concern of many 
IRBs and genomic researchers is that by returning research results and having individuals 
(and/or their physicians) act on the result, medical care, rather than research, is being 
practiced [2]. As genomic technologies allow for more detailed analysis of the human 
genome, clinically relevant research findings will be discovered, both related and unrelated 
to the scope of the original study. In this paper, we address whether and how the return of 
research results from PGx studies may be different from results from disease susceptibility 
studies (DSS).
The goals of this paper are to: analyze the ethical implications (risk of harm and anticipated 
benefits) of returning individual research results to research subjects from PGx studies 
compared with DSS; identify factors that need to be considered when making decisions 
about return of individual PGx compared with DSS genomic research results; and present an 
argument supporting the return of PGx research results that predict serious adverse events.
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Arguments for & against return of individual research results
Most investigators in the USA would probably not have a problem sharing the findings of 
the scenarios described above with another colleague; the author has observed this type of 
data sharing for more than 20 years. Yet there are considerable differences of opinion about 
sharing this information with the research participant and/or their treating physician 
[2,3,11,12]. Proposed recommendations addressing the issue of return of results frequently 
involve the researcher as part of the process to determine whether or not a research result 
should be returned [2]. Since the researcher is the first observer of the finding, he/she would 
need to take the first step to bring the observation to the attention of an oversight body (i.e., 
IRB, advisory group and so on). However, most recommendations, including the National 
Bioethics Commission [102], indicate that if a research result is to be returned, it should be 
communicated by a trained medical professional (e.g., medical geneticist or genetic 
counselor), not by the genomic researcher [1,3,13]. Although in the international setting 
there is an emerging ethic for research results with clinical or health relevance to be returned 
to research participants [14], traditionally in the USA, the research community has followed 
a ‘nondisclosure’ policy [1]. To begin the ROR discussion, it is important to review the 
arguments both for and against return of individual research results [1].
Arguments for the return of individual research results often cite the ethical principle of 
respecting the autonomy of the research subject; those individuals who want to know 
research information learned about them should be able to obtain those results [1,2]. Some 
argue that returning results is a form of reciprocity for the individual’s participation in the 
study [1,2]. Those in favor of return indicate that the result may be of value to the research 
subject – it may have personal meaning (e.g., empowerment – knowledge is power), help 
make lifestyle decisions (e.g., change diet or take out long-term care insurance) and/or be 
clinically important (e.g., predicting immediate or long-term health risk) [1,2]. The ethical 
principle of non-maleficence is also cited to support return of research results, especially 
when the result could help prevent or ameliorate a medical condition. However, many 
supporters also recognize that research results may need to be withheld in certain 
circumstances, especially when disclosure would predictably compromise the safety of a 
participant or third party or would compromise the scientific validity of the study [1]. In 
addition, even among supporters, most agree that only validated results should be returned. 
What constitutes a validated result, however, is still unclear [1,2].
Arguments against return of individual research results also cite the ethical principles of 
respect for autonomy and non-maleficence but have different perspectives on how and why 
these principles apply [1]. Some indicate that by not returning research results, a researcher 
is respecting the autonomy of a research subject who initially agreed to participate in the 
study under conditions of nondisclosure [1]. The National Bioethics Advisory Commission 
recommended that a clear statement be included in the consent document indicating whether 
or not results would be disclosed, and if yes, what the risks associated with that disclosure 
might be [1,102]. Until recently, however, most consent documents have indicated that 
results of research would not be returned to research participants. The most common 
arguments for not returning research results include the following: unconfirmed (or 
unvalidated) results may do more harm than good (e.g., an inaccurate finding may lead to 
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unnecessary psychosocial distress and potential for discrimination); by law, in the USA, 
only Clinical Laboratory Improvement Amendment (CLIA)-approved laboratories can 
provide results for treatment decisions [103] (until recently, it was rare to have a 
researcher’s laboratory be CLIA-approved and therefore return of results was considered by 
some as a nonissue); and returning research results was contrary to the intent of research, 
which is to provide generalizable results for the public’s benefit, not for individual benefit 
[1].
However, as investigators utilize new genomic technology, (e.g., whole-genome 
sequencing) and discover more health-related information, and as social scientists conduct 
studies of the consequences of returning genomic results to research subjects, the concept of 
what is considered ‘research’ is likely to evolve as will the arguments on either side of the 
issue of return of research results.
Questions, assumptions & guides
In the context of return of individual research results, the main questions addressed in this 
paper are the following: are results from PGx studies, especially those predicting an adverse 
event (PGxAE), different than results from DSS?; and how do the ethical implications and 
consequences (potential for harm and anticipated benefits) of returning a research result 
from these two types of studies compare? This comparative assessment is limited to studies 
of inherited (germline) DNA variations or mutations in adults. For a PGxAE result, this 
would include a polymorphism(s) or variation(s) in one or more genes associated with an 
adverse response or toxicity to drug X. For a disease susceptibility result, this would include 
a variation(s) or mutation(s) in one or more genes associated with development of disease A 
(Box 1).
Box 1
Context of risk–benefit assessment
• The context of the risk–benefit assessment is focused on research results from 
pharmacogenomics studies predicting toxicity or adverse events (PGxAE) and 
disease susceptibility studies predicting future development of disease. Our 
assessment will be limited to inherited (germline) DNA variations or mutations. 
For a PGxAE result this would include polymorphism(s) or variation(s) in one or 
more genes associated with an adverse response to drug X. For a disease 
susceptibility result this would include variation(s) or mutation(s) in one or 
more genes associated with development of disease A.
Assumptions
The assessment begins with the following assumptions: research subjects have the right to 
control whether they learn research results about themselves or not [2]; genomic researchers 
agree that it is their responsibility to consider the clinical relevance of a finding and act on 
those that pose imminent risks of severe, preventable harm to the subject, by reporting this 
to the Principal Investigator and/or the IRB or an oversight body [11]; preliminary, 
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unvalidated results should not be returned to research subjects [1–3]; and if results are 
returned, medical professionals expert in communicating genetic/genomic findings to 
individuals (e.g., a medical geneticist or genetic counselor), should return the results, not the 
research investigator (Box 2) [1,2].
Box 2
Assumptions of risk–benefit assessment
• Research subjects have a right to know and a right not to know research results.
• Genomic researchers agree that it is their responsibility to consider the clinical 
relevance of a finding and act on it (i.e., report to Principal Investigator or 
responsible oversight body).
• Preliminary unvalidated results should not be returned.
• Results should only be returned by medical professionals expert in 
communicating these findings, not the research investigator.
Guides & definitions
As a guide for this assessment, conditions for return of individual research results 
recommended by the National Heart, Lung and Blood Institute (NHLBI) [3], integrated with 
recommendations from the Incidental Findings Working Group (IFWG) [5] were used. 
Traditional variables used in information disclosure were also incorporated. These included 
analytic validity, clinical validity, predictive value and clinical utility (as defined by/
available through the CDC [15,104–106]).
NHLBI conditions for return of research results
Two NHLBI recommendations address the criteria necessary to determine when genetic 
results ‘should’ or ‘could’ be returned to study participants [3]. Both of these 
recommendations are built on the premise that informed consent has been obtained and that 
the study participant’s identity and contact information is available. Return of individual 
results does not apply to anonymous studies or secondary analysis where there is no means 
to re-identify or recontact participants. NHLBI recommends that the investigator, along with 
the IRB, and ideally through a central advisory board including other experts, make the 
determination regarding when results should or could be offered to the research participant.
NHLBI recommendation for when results should be offered—According to 
NHLBI, “Individual genetic results should be offered to study participants if they meet all of 
the following criteria: a. the genetic finding has important health implications for the 
participant, and the associated risks are established and substantial; b. the genetic finding is 
actionable, that is, there are established therapeutic or preventive interventions or other 
available actions that have the potential to change the course of the disease; c. the test is 
analytically valid, and the disclosure plan complies with all applicable rules; and d. during 
the informed consent process or subsequently, the study participant has opted to receive his 
or her individual genetic results” [3].
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NHLBI recommendation for when results could be offered—NHLBI also offered 
recommendations for when a result could be offered: “Investigators may choose to return 
individual genetic results to study participants if the criteria for an obligation to return (i.e., 
should return) are not satisfied, but all of the following apply: a. the investigator has 
concluded that the potential benefits of disclosure outweigh the risks from the participant’s 
perspective; b. the investigator’s IRB has approved the disclosure plan; c. the test is 
analytically valid and the disclosure plan complies with all applicable laws; and d. during 
the informed consent process, or subsequently, the study participant has opted to receive 
his/her individual genetic results.” Part A of this recommendation relies on the investigator’s 
judgement to assess the risks and benefits from the research subject’s perspective and 
include individual results associated with reproductive risks, and those that have personal 
meaning or utility or health risks in select circumstances [3].
IFWG
The recommendations from IFWG focused on the return of ‘incidental’ findings. They were 
based on the net benefit of returning the finding to the research participant [5]: results of 
strong net benefit should be disclosed; those with possible net benefits could be disclosed 
and those with unlikely net benefits should not be disclosed (unless the participant elected to 
know). In general, recommendations were influenced by whether the result revealed a life 
threatening or serious condition for the individual or their offspring that could be avoided or 
ameliorated (should disclose); revealed a condition that could not be avoided or ameliorated 
but was still grave or serious yet non-fatal (may disclose); or that the results were not likely 
to be of serious health or reproductive importance or whose importance cannot be 
ascertained (do not disclose). Except for the focus on reproductive decision-making, many 
of the IFWG conditions for ‘return’ or ‘may return’ were subsumed in the NHLBI 
recommendations.
CDC model for genetic testing
The definitions provided by the CDC Analytical Validity, Clinical Validity, Clinical Utility 
and Ethics (ACCE) Model for Genetic Testing [103] (and incorporated by Evaluation of 
Genomic Applications in Practice and Prevention [EGAPP™] [104]), were also used to 
guide our assessment. These definitions (Analytical Validity, Clinical Validity and Clinical 
Utility) along with other terms used in this paper are summarized in Box 3. In brief, analytic 
validity refers to how accurately and reliably the test (or result) measures the genotype of 
interest; clinical validity refers to how well the result detects or predicts the associated 
disorder (disease) or condition (response to therapy); and clinical utility refers to how 
effective the result is at avoiding or minimizing adverse clinical consequences (prevent/
reduce severity of disease or prevent/reduce severity of adverse drug response).
Box 3
Definitions used to guide the risk–benefit assessment
Related results
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• Research results with potential health or clinical relevance that are related to the 
aims or scope of the study [1].
Incidental results
• Research results with potential health or reproductive importance; discovered in 
the course of conducting research, but are beyond the aims of the study [5].
Analytic validity
• Accurately and reliably measures the genotype of interest; includes analytic 
sensitivity and specificity, laboratory quality control and assay robustness [104].
Clinical validity
• Detects or predicts the associated disorder or condition; includes clinical 
specificity, positive predictive value, negative predictive value and prevalence 
of specific disorder [104].
Predictive value
• The ability to predict disease or treatment response. Positive predictive value is 
the absolute risk of developing the disease or response in carriers of the 
mutation or variation. Negative predictive value is the probability that 
noncarriers will not develop the disease or response [15].
Clinical utility
• Availability and effectiveness of intervention to avoid/minimize adverse clinical 
consequences [104].
Similarities & differences between PGx & DSS results
Research results from PGx and DSS share many features. Both types of results are 
predictive and probabilistic in nature. PGxAE predicts the risk of developing an adverse 
response to a drug; DSS predicts the risk of developing future disease. Both types of results 
have varying degrees of uncertainty regarding whether the risk estimate is correct. Research 
results both related and incidental to the original aims or scope of the research may be 
obtained in either type of study. Results from both PGxAE studies and DSS may have 
important health implications for the research participants and because of this, for both types 
of studies, research participants may want to know the research result. When conducting 
either type of research, it is important to clearly communicate to the research subject the 
tenuous nature of research and how associations between variations and outcome may 
change as time goes on and more is understood about the disease or drug therapy.
PGx, DSS & the continuum of health & disease
Although PGx and DSS results share many similarities, important differences also exist. To 
highlight some of these differences, we will first briefly examine the temporal relationships 
of these results along the dynamic continuum of health and disease. From the schematic in 
Figure 1, an individual can move through a continuum of being in a healthy state to being in 
a state of disease. Once the individual is diagnosed or develops a disease or condition, 
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treatment, if available, is usually sought. If the individual is aware of the potential to 
develop disease and there is an intervention available, it may be possible to prevent the 
disease from occurring or at least minimize the severity of disease. This is also true if the 
individual is aware of the potential to develop an adverse response to a drug. In this 
continuum, disease development (Tx) and treatment response (Ty) are considered as two 
separate events. Recognizing that many different contexts are possible, in general, when 
disease susceptibility is predicted in an otherwise healthy individual, there is often a long 
timeframe (e.g., decades, years) until the event (Tx). By contrast, when an adverse drug 
response is predicted (PGxAE), especially in a patient with a disease diagnosis, there is often 
a short timeframe (e.g., weeks, days or hours) to the event (Ty). Even when an individual is 
otherwise healthy, the prediction of an adverse drug reaction (e.g., an incidental finding 
predicting an adverse response to codeine) may be equally time sensitive and have a short 
time to the event. When the predicted PGx event relates to drug effectiveness (PGxEFF), 
however, the time to the event (Tz) can often take months or years (e.g., measuring 
effectiveness of chemotherapy as time to tumor recurrence or death [16]).
It is also recognized that the implications of returning a research result to an otherwise 
healthy individual will be different compared with an individual already diagnosed with 
disease. DSS predictions often involve healthy individuals, while PGx predictions related to 
adverse events (PGx AE) are often associated with individuals already diagnosed with 
disease. Even when DSS are conducted with diseased individuals, the stigma of disease, if it 
exists, is already present, and the prediction of developing another condition is still in the 
future. It is also important to recognize the difference between a DSS and a PGxAE event in 
relation to clinical care. The PGx AE research result is often obtained when an individual is 
either considering or undergoing treatment (prospective study) or has already received 
treatment (retrospective study) – that is, the research participant is already involved in the 
clinical care setting. By contrast, the DSS result, especially for healthy individuals, is 
frequently obtained when the research participant is not involved in clinical care. Unless 
there is a medical intervention available to prevent the disease, a PGxAE prediction is more 
closely associated with clinical care compared with DSS.
When should results from PGx & DSS be returned? Applying NHLBI criteria
Applying the NHLBI criteria for when research results should be returned [3], it was 
assumed, for both the PGx AE and DSS research result, that the following NHLBI conditions 
were met: the result was analytically validated and may have important health implications 
for the individual research participant; during the informed consent process or subsequently, 
the research participant opted to receive her/his genomic results; and the disclosure plan 
complies with all applicable laws [3]. With these conditions fulfilled, the remaining NHLBI 
criteria were applied to each type of result and included the following: first, the associated 
risks are established; second, the associated risks are substantial; and third, the result is 
medically actionable (intervention or prevention available) [3]. In developing the NHLBI 
criteria for when results should be returned, the working group did not designate a firm 
threshold of risk, because they considered that the importance of genetic information to a 
study participant would depend on the magnitude of the risk as well as its consequences. For 
Dressler Page 8













the current assessment, an additional criterion, from the IFWG, was also incorporated: 
fourth, the result would be useful in reproductive decision-making [5].
Using these four conditions, we compared how well PGxAE versus DSS results met the 
criteria for when a result should be returned (see Table 1). For both the PGxAE and DSS 
result, applying the first two criterion, the associated risks may (+) or may not (−) be 
established and the risks could be substantial (++). The DSS result might be useful in 
reproductive decision-making (++) [17,18]; however, a PGx result indicating lethal- or high-
grade toxicity to a drug would probably not be relevant to decisions about reproduction (+/
−), unless it predicted harm to a fetus, pregnant woman or side effects altering fertility. 
Turning to the third criterion, the medical actionability of a PGx result is likely to be high (+
++), because in theory all PGx results predicting an adverse event have an intervention or 
could be prevented. This is because of the choices that PGx data make possible: whether to 
forego the drug or drug dose; whether to give an alternative drug; or whether to increase 
monitoring and add supportive therapy if no alternate drug is available [7]. By contrast, the 
medical actionability of DSS results, as defined by NHLBI, depend entirely on whether or 
not there exists an established intervention or prevention or other action to alter the course of 
the condition and lead to improved outcome [3]. Medical intervention for DSS results are 
much less likely compared with PGxAE results. Following the NHLBI criteria, medical 
actionability is the main difference between the two types of results when deciding to return 
results.
The overall benefit of returning a PGx AE result compared with a DSS result was also 
assessed, including the prospect for personal meaning, clinical benefit, clinical utility, and 
time to clinical benefit (Table 2). For both types of research results, the research subject may 
benefit personally from the knowledge or meaning he/she associates with the research result. 
However, compared with DSS, PGxAE results have a higher prospect for clinical benefit 
because there is likely to be clinical utility and medical actionability. It is also likely that the 
research subject may have clinical benefit sooner with the receipt of PGxAE versus DSS 
results, especially if he/she is continuing to receive treatment for their condition and the 
PGx AE result can prevent a severe or life-threatening toxicity from a subsequent drug.
Leveling the playing field
To allow the results from PGxAE and DSS to be more similar, let’s now assume that the 
research results from both studies are medically actionable – that is, have clinical utility 
(Box 4). This removes the main difference between the two kinds of results observed in the 
assessment above. When clinical utility is similar, the focus of the assessment shifts to 
clinical validity – the association of the research result with a clinical condition or treatment 
response. Analyzing clinical validity includes evaluating the risks and benefits of returning a 
false-positive result as well as the ethical implications of not returning (i.e., withholding) a 
true-positive result, especially results with high positive-predictive value.
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Leveling the playing field
• To allow the results from a pharmacogenomics study predicting drug adverse 
events (PGxAE) and disease susceptibility studies to be more similar, we then 
assumed that the research results from both studies were medically actionable 
thus removing the largest difference we had observed in the initial assessment. 
When clinical utility is similar, the focus of the assessment shifts to clinical 
validity, including the risks and benefits of returning a false-positive result and 
the risks and benefits of not returning a true-positive result, especially results 
with high positive-predictive value.
Harm in returning a false-positive result
Table 3 summarizes the potential harms (clinical, psychosocial, reproductive and economic) 
of returning a false-positive PGxAE versus DSS result to the research subject. In general, for 
PGxAE, the clinical or health harm in returning a false-positive research result might include 
the following: the individual would not be given a potentially effective drug (because the 
research result predicted an adverse event); the individual might be given an alternate drug 
not as effective as the original drug; and/or the alternate drug could cause an adverse event 
(especially if no test existed to predict response to that drug). In addition, if no alternative 
drug was available and the drug was administered, the individual may be anxious about the 
predicted adverse effect and be needlessly monitored or given supportive therapy to offset 
the falsely predicted toxicity.
By contrast, the consequences of returning a false prediction that an individual would 
develop a disease for which there exists a medical intervention might subject the individual 
to receive unnecessary treatment to prevent the disease. The treatment may lead to other 
clinical or health-related harms (e.g., pain, hair loss, harm to organ systems [liver, kidney, 
heart and so on]). The potential for psychosocial harm, including emotional consequences 
(e.g., anxiety, worry and depression), stigmatization, family discord and change in career 
path would be more likely to develop from returning a false-positive DSS compared with 
PGxAE results. Studies in the literature document the concern for these negative 
implications, consequences and stigma associated with an individual research participant 
learning about the potential to develop certain diseases (e.g., cancer, mental illness and 
Alzheimer’s disease) [2,19,20]. Although fears of blood draws, mistrust of researchers and 
the healthcare system and confidentiality concerns about genetic testing have been raised for 
both PGxAE and DSS [21], the public may perceive a PGxAE result to be associated with 
less harm for stigmatization and discrimination, and possibly more good (because they could 
do something about it) compared with learning about the risk of disease development. This 
reasoning stems from the likelihood that more people are familiar with and have had the 
experience of suffering a side effect from taking a drug, compared with the experience of 
being diagnosed with or having the susceptibility to develop a chronic or life-threatening 
disease.
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The return of false-positive results from both PGxAE and DSS research may also have 
harmful economic consequences. Returning the PGx result may cause the individual to pay a 
higher price for the alternate drug and/or the potential that the insurance company may not 
cover that costly drug; the DSS result may cause the individual to suffer a drop in income 
due to a change in career path and additional costs if he/she decides to purchase long-term or 
additional life insurance.
Consider the situation where a DSS result falsely predicts development of a neuro-muscular 
disorder in midlife compared with a PGxAE result which falsely predicts transient 
neuropathy in response to taking a drug for treating the disorder. Here, the return of the DSS 
result is likely to have a significant effect on reproduction, including the decision to have 
children, the decision for existing children or other blood relatives to receive testing or if no 
testing was available, the consequence that other family members may receive unnecessary 
treatments hoping to prevent the disease.
In general, compared with PGxAE, we considered the risks of returning a false-positive DSS 
result to have the potential to lead to more harm and less benefit for the research participant.
Harm in not returning a correct result
Table 4 summarizes the harm of withholding a correct result, especially a result with a high 
positive-predictive value. We considered that withholding this kind of PGxAE result is likely 
to have the potential for significant clinical harm. The research participant may develop a 
lethal side effect and die from taking the drug or drug dose. If not lethal, the individual may 
develop a serious adverse event and may need to be hospitalized. Harmful clinical 
consequences of not returning a correct DSS result are that the individual may develop a 
disease that could have been prevented or may not have taken steps to ameliorate or 
otherwise prepare for the disease or its consequences. With a genetic disease that lacks a 
preventive intervention, but is associated with a highly penetrant mutation, the individual 
may still develop the disease and receive clinical treatment, if available, at that future time. 
In contrast to DSS, we often cannot wait for a PGxAE event to occur to intervene or 
ameliorate its effect, especially if it predicts a lethal event.
Significant psychosocial consequences could occur when the result, either PGxAE or DSS, 
predicts a preventable condition [1]. However, since most genomic diseases lack a 
preventive intervention, it is likely that withholding a correct DSS result will result in less 
harm compared to withholding a correct PGxAE result (which, in theory, is always 
associated with a medical intervention). If a correct DSS result is withheld for a non-
preventable disease, the individual and/or their family will not have benefited from the 
potential personal utility (i.e., personal meaning, empowerment and life choices) of 
anticipating the development of the disease. The individual may feel a wide variety of 
emotions (e.g., anguish, anger, despair and frustration) upon developing the disease, which 
may or may not have been mollified by having had previous knowledge of the impending 
condition. Other individuals, who do not derive any personal meaning or empowerment 
from learning their disease susceptibility, may actually benefit psychologically from not 
knowing the result’s prediction.
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Reproductive consequences are more likely to be significant for DSS compared with PGxAE 
results, especially if the individual might have used the DSS result to decide not to have 
children or additional children. Economic consequences could be significant for withholding 
both DSS and PGx results.
Overall, in this assessment, not returning a correct PGxAE result is considered more harmful 
than not returning a correct DSS result (unless an intervention exists to prevent the predicted 
disease or there are serious reproductive consequences) (Box 5).
Box 5
Returning a false-positive result
• In general, compared to a pharmacogenomic result predicting an adverse event, 
PGxAE, result, we considered the harms of returning a false-positive disease 
susceptibility study result to lead to more harm for the research participant, 
especially related to psychosocial and reproductive implications, as well as the 
potential for more long-term economic harm.
Summary
Thus far in this comparison, several differences have been identified that distinguish PGx AE 
from DSS research results (Box 6). Compared with DSS, PGxAE results are medically 
actionable, may offer benefit immediately and may be more closely related to the clinical 
care setting. In general, compared with DSS results, PGxAE results are associated with less 
psychosocial and life choice consequences: the return of an incorrect PGxAE result is likely 
to result in less harmful consequences for the research subject; and result is likely to 
withholding a correct PGxAE result in more harmful consequences. Overall, the ethical 
implications (i.e., potential for risk of harm versus anticipated benefit) favors the return of 
analytically and clinically validated PGxAE results compared with DSS results. However, 
the decision to return or withhold research results, whether PGxAE or DSS, should be made 
on a case-by-case basis, and will be influenced by the contextual nature of the research 
result and the research participant’s desire to know the result [1,2,102].
Box 6
Summary: returning PGxAE results versus disease susceptibility study 
results
• Our assessment has identified several differences between research results from 
pharmacogenomics studies predicting adverse drug events (PGxAE) and disease 
susceptibility studies: PGxAE results are medically actionable; PGxAE results 
may offer benefit immediately; in general, PGxAE results are associated with 
less psychosocial and life choice consequences; in general there is less harm if 
an incorrect PGxAE result is returned and more harm if a correct PGx result is 
not returned. Overall, our risk–benefit assessment favors the return of 
analytically and clinically validated PGxAE results compared with disease 
susceptibility study results. The actual decision to return or withhold research 
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results should be made on a case-by-case basis and will be influenced by the 
contextual nature of the finding and the research participant’s desire for the 
result.
When could results be offered? Applying NHLBI recommendations
NHLBI criteria also address when research results could be returned to the research 
participant. These criteria are based on the investigator’s (and the IRB’s) judgement of the 
net benefit of returning results from the perspective of the research participant [3]. The 
recommendation is largely subjective and will be heavily influenced not only by the context 
of the result but also the point of view of the investigator (and IRB) in making this 
assessment. Return of PGx AE results continues to demonstrate a higher net benefit for the 
research participant compared with DSS results because in theory, all are medically 
actionable, and, for some results, the time to benefit may be quite soon. Therefore even 
though there is some uncertainty associated with the risk of developing the adverse response 
or the magnitude of the adverse response, it is likely that a research participant would want 
to learn of a result that has some chance of preventing physical harm. Furthermore, as 
discussed in the assessment above, psychosocial and reproductive issues are likely to be 
more significant for DSS compared with PGxAE. So, results from PGxAE studies are more 
likely to be considered by investigators and IRBs to have a higher net benefit compared with 
results from DSS studies.
Therefore to address when results should or could be shared with the research participant, 
one must consider the types of PGx AE results that have a higher net benefit than others. In 
the following section, we integrate parameters derived from the assessment presented in this 
paper (including recommendations by NHLBI and IFWG) with an adaptation of a proposed 
system for returning incidental findings from whole-genome sequencing results [4].
Return of pharmacogenomic results that predict an adverse event: 
adapting the ‘bin’ approach
Returning or withholding research results is very context dependent and is influenced by 
whether the individual research subject wants to know the results [1–3]. Many individuals 
and groups have recommended that only analytically validated results, with a known 
medical intervention, should be returned [1,3,4,102]. In this paper, it is also argued that the 
ethical decision to return PGxAE results turns on both the risk of harm in withholding an 
accurate research result and the risk of harm in returning a false-positive research result 
(where harm includes clinical, psychosocial, reproductive and economic harm). A critical 
question in this paper regarding the decision to return a PGxAE research result that is 
‘related’ to the study aims, is whether one should wait until the finding is considered a 
clinical result – that is, an established test that is used in clinical care – or return the result at 
some point in time before the process of clinical translation has occurred.
Although the ‘bin’ approach, described by Berg et al. is intended for making decisions 
regarding return of incidental (not related) results in the clinical (not the research) setting, it 
can be adapted to guide the return of PGxAE research results [4]. In the bin approach, similar 
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to the approach in this paper, guidance for return of results from whole-genome sequencing 
assays is determined by the results’ clinical relevance: bin 1 results demonstrate clinical 
utility and are medically actionable; bin 2 results demonstrate clinical validity; and bin 3 
results have unknown clinical implications. Similar to the approach we have taken in this 
paper, bin 2 results, are further categorized based on the level of risk or harm that would be 
expected if the result was to be returned to the individual [4]. In addition, for a genomic 
variant to be reportable (in the clinical context), the bin approach considers whether the 
variant will have a ‘known’ or ‘presumed’ deleterious effect (in which case the result, if 
medically actionable, is reportable) or whether the variant is presumed or known to be 
benign or is a variant of uncertain clinical significance (in which case the result, even if 
medically actionable, is not reportable) [4].
Proposed guidelines for the return of PGxAE results
In this article we have argued that PGxAE research results are, in theory, medically 
actionable, and that often these results, if returned, will likely have low to medium risk of 
harm to the individual. Applying the bin conditions (i.e., prediction of a deleterious, benign 
or unknown clinical effect) and combining them with toxicity grades [107,108], we present a 
framework for the return of PGxAE results. This framework can be utilized to guide 
decisions, whether the PGxAE results are related or incidental to the study aims.
We propose the following guidelines (also see Table 5).
Should be returned—Results that are known or presumed to be deleterious (based on 
previous literature or retrospective studies) and are medically actionable should be returned 
to the research subject and do not require a prospective clinical validation study to warrant 
return. Examples of these types of research results include: PGxAE research results that 
predict a lethal response to a drug or drug dose (e.g., anaphylaxis or Stevens–Johnson 
syndrome). This position is based on the understanding that the prediction of a lethal result 
always has an intervention-do not give the drug. If the result is withheld but is correct, the 
individual may die; even if the result, in subsequent prospective validation studies, turns out 
to have a low–medium predictive value, the risk of return is still reasonable compared with 
the potential harm. PGxAE results that predict serious responses, including those that predict 
a response likely to require hospitalization (e.g., cardiac toxicity), likely to be disabling 
and/or permanent (e.g., permanent peripheral neuropathy; blindness) and/or those that would 
seriously limit daily adult function (e.g., severe vomiting or migraines) should also be 
returned even in the absence of a prospective clinical validation study because the net 
benefit to the research subject is likely to be high. If the result is withheld but is correct, the 
individual may suffer physical, psychosocial and economic harm, not being able to work 
and/or requiring additional at home care for themselves or their family. If the result is 
returned and, in subsequent prospective validation studies turns out to have a low–medium 
predictive value, the risk of altering medications or providing additional monitoring and 
therapeutic support based on the result is still reasonable compared with the potential harm.
Should not be returned unless confirmed in a prospective study—Results that 
are known or presumed to predict serious, but not life-threatening responses, that are 
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unlikely to require hospitalization, but may result in temporary (reversible upon drug 
discontinuation) toxicity (e.g., temporary peripheral neuropathy or moderate neutropenia) 
should not be returned unless confirmed in a prospective clinical validation study (clinical 
trial or alternative study design) and a medical intervention exists.
Should not be returned—Results that are uncertain or predict presumed or known 
benign responses should not be returned. Examples of these types of research results include 
the following: PGx results that predict mild, temporary drug responses (e.g., nausea, 
diarrhea, mild skin rash) that will either resolve in a reasonable time or are treatable by over 
the counter or prescription medication and that do not impose an economic burden on the 
family or individual, should not be returned. Overall, there is little or no net benefit, 
clinically or economically, in returning the result. The drug will still be utilized and the 
response to the drug can be managed reasonably. PGx variants of uncertain clinical 
relevance might be useful in the future and, depending on the nature of the variant and 
resources, the researcher may consider maintaining a registry of these results, and/or 
monitoring the clinical relevance over time and/or invite research subjects to participate in 
future research.
Other considerations
Comparing results of PGx studies evaluating treatment effectiveness versus DSS
Although this paper has focused on PGx AE results, many pharmacogenomic studies also 
evaluate the effectiveness, rather than the adverse effects, of a drug or drug regimen to treat 
a disease (PGxEFF). In the author’s experience, especially conducting cancer genomic and 
genetic research, in contrast to PGxAE, but similar to DSS, PGxEFF studies generally predict 
a future rather than a more immediate event. Similar to DSS, PGxEFF may require several 
years to observe an outcome (e.g., risk of disease recurrence or risk of disease development). 
By contrast, PGxAE results may only take a few days, weeks or months to observe the toxic 
event (e.g., development of peripheral neuropathy). Both DSS and PGxEFF results could 
have significant clinical, psychosocial and economic consequences for the individual. In 
contrast to PGxAE, returning a false-positive result or withholding a result with high 
positive-predictive value from either DSS or PGxEFF studies, may have similar clinical 
consequences. The factors that influence decision-making regarding return or withholding 
results from DSS and PGxEFF may be more similar than different. In other words, the factors 
that distinguish PGx AE from DSS – the potential for a more rapid time to benefit, less harm 
if an incorrect result is returned, more harm if a correct result is withheld, and less potential 
for psychosocial harm – may not apply when comparing the return of PGxEFF versus DSS 
results. It follows therefore that, overall, the return of results from PGxEFF and DSS may be 
more similar than different.
Pleiotropy, DSS, PGx & return of results
Although this paper has discussed return of individual results in the context of genomic 
variations predicting a single response or disease, polymorphisms or mutations may have 
more than one effect [22]. This situation, known as pleiotropy, adds another layer of 
complexity in deciding whether to return or withhold research results. For example, 
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variations in the APOE4 gene are associated with cardiovascular disease, risk of 
Alzheimer’s disease and progression to HIV+/AIDs-predicting susceptibility to three 
different conditions [23]. Variations in the CYP2D6 gene are associated with response to the 
drug tamoxifen [24–26], but are also associated with response to many other drugs that are 
metabolized by or influenced by the CYP2D6 enzyme, including codeine and selective 
serotonin re-uptake inhibitors, respectively [26]. Mutations in the BRCA1 gene may predict 
susceptibility to developing breast and ovarian cancer (DSS) and may also be useful in 
predicting effectiveness (PGxEFF) to cancer agents [27]. As we learn more about pleiotropic 
associations (diseasea–diseaseb, responsea–responseb, and diseasea–responseb), we will need 
to consider their effect on the ethical implications and decision to return individual research 
results. In time, the distinction between a PGxAE result and DSS result may be less 
important than the overall ethical implications of finding results that are pleiotropic 
compared with those that are not.
Conclusion
The return of any individual result requires a careful assessment of the potential risks and 
anticipated benefits and the ethical implications of such return to the individual and/or their 
family. This includes the clinical/health, psychosocial, reproductive and economic impact of 
receiving and acting on the result. Because each situation is context dependent, the decision 
to return an individual research result should be made on a case-by-case basis. However, 
these decisions can be guided by the following conditions and observations. The return of 
any individual research result requires analytical validity. Compared with disease 
susceptibility results, pharmacogenomic results from studies predicting adverse response to 
drugs (PGxAE) are medically actionable, may offer benefit immediately, and are likely to be 
associated with less psychosocial and life-choice consequences. Compared with a DSS 
result, it is likely that less harm will be associated with returning a false-positive PGxAE 
result and more harm will be associated by withholding a correct PGx result. Therefore, the 
return of PGxAE results must be guided by the expected toxicity and the clinical and ethical 
implications of that response if the individual were to receive the drug or drug dose. In 
addition to analytic validity, most results should also be clinically validated in a prospective 
study. However, PGxAE results predicting a lethal toxicity and those predicting serious or 
life-threatening drug responses should be returned even in the absence of a prospective 
clinical validation study if they meet our guidelines. Uncertain results (i.e., analytical 
validity not established) or those with little or no clinical or personal benefit to the research 
participant should not be returned since the risk of harm is high and there is no net benefit.
Future perspective
The challenges and controversies surrounding the return of individual research results are 
likely to be minimized as empirical studies analyze the process of how these decisions are 
made, how results are communicated to research subjects, what kind of results research 
subjects want and the actual consequences of returning (or not returning) individual research 
results. Whether from PGx or DSS or other ‘omic’-based studies, it is likely that in the near 
future federal guidance and best practices, informed by these empirical studies will be 
forthcoming. This guidance will likely include general conditions for deciding when 
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research results should be returned and how this process should proceed, including what 
steps a researcher should take if he/she discovers a health-related result, and who should be 
responsible for making the decision. Guidance should also be forthcoming not only on who 
should communicate this information, but how it should be communicated and to whom. In 
addition, guidance should be forthcoming on how to address the responsibility of recontact 
if new data influences interpretation of results that may or may not have been initially 
returned. In the future, it is also likely that there will be more efficient translation of 
genomic research findings into the clinical setting, especially for PGxAE results. Electronic 
medical records will be including genomic profiling results that can be useful for clinical 
management, especially with advances in health information technology to integrate this 
information [28]. We will be developing rapid learning systems [29], point-of-care 
applications and other educational approaches for clinicians to be able to evaluate this 
information and stay up-to-date with emerging discoveries. We will be developing patient 
portal systems to capture patient reported outcomes and provide more individualized 
education according to patient needs. But for many of these advances to take place, the key 
players will need to agree on some standards of reference for determining analytical and 
clinical validation of a research result. We will need to determine how much risk or 
uncertainty is reasonable to warrant return of the results and seriously consider the costs to 
patients, the healthcare system and the public to develop (or not) an infrastructure required 
to support this. For those who are interested and can afford it, personal genomic sequencing, 
of varying degrees of quality, will be available from the private sector, outside the research 
or clinical setting, and will provide an option for some interested in receiving results about 
their genome.
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• As genomic technologies allow for more detailed genomic analysis, clinically 
relevant findings, both related and unrelated to the scope of the original study, 
will be discovered. In the context of the controversial issue of return of 
individual research results, how does returning results from pharmacogenomic 
(PGx) studies compare with disease susceptibility studies (DSS)?
Arguments for & against return of individual results
• The main argument in support of returning research results is respect for 
research participant’s autonomy as a research participant; the main argument 
against return is that it may do more harm than good, especially if the finding is 
preliminary or not validated. One of the main challenges in deciding whether or 
not to return research results is that doing so crosses the boundary between 
research and clinical practice.
Conditions guiding the comparative assessment of returning individual research 
results from PGx studies versus DSS
• Guided by the recent National Heart, Lung and Blood Institute criteria for return 
of individual research results, the potential risks and anticipated benefits were 
compared for returning results from PGx studies, especially research results 
predicting an adverse event (PGxAE), with results from DSS.
Similarities between PGx & DSS research results
• Both types of results are predictive and probabilistic, are associated with results 
both related and incidental to the study aims and may have important health 
implications for the research participant.
Differences between PGx & DSS research results
• Medical actionability and time to benefit are the two most striking differences 
between the two types of results: in theory, all PGxAE results are medically 
actionable (do not give drug or drug dose) and, compared with DSS results, 
PGxAE results are more likely to have an earlier/immediate benefit to the 
research participant.
Harm in returning a false-positive result
• Even when both types of results are medically actionable, there is likely more 
harm (especially psychosocial, reproductive and economic consequences) in 
returning a false-positive DSS compared with PGxAE result.
Harm in not returning a correct result
• In the situation where a research result has a high positive-predictive value, the 
research participant is likely to suffer more harm from withholding a PGxAE 
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compared with a DSS result (unless an intervention exists to prevent 
development of the predicted disease).
Conclusion
• Overall, compared with DSS results, PGxAE results are medically actionable, 
may offer benefit immediately, have less harmful consequences if an incorrect 
result is returned, and more harm if a correct finding is withheld. We conclude 
that PGxAE results are different than DSS results. Our risk–benefit assessment 
supports the return of analytically validated PGxAE results that predict lethal or 
high-grade adverse events. Owing to the highly contextual nature of genomic 
research, a case-by-case risk–benefit assessment is required.
Future perspective
• Although some federal guidance will be forthcoming, the eventual integration of 
certain genomic results into medical records will occur, requiring a careful 
curation, analysis, and evaluation of which PGx findings are medically 
significant and could be acted upon, even before they have become ‘standard-of-
care’ tests.
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Figure 1. Health–disease–outcome continuum
As an individual moves along this continuum, he/she moves from being in a healthy state to 
being in a diseased state, with some type of outcome. When a DSS result is obtained (Tr) it 
can often result is obtained take years before the event occurs (Tx). By contrast, when a 
PGxAE (Tr) it may only be days or weeks before the event occurs (Ty).
DSS: Disease susceptibility study; PGxAE: Pharmacogenomics study predicting drug 
adverse events; PGxEFF: Pharmacogenomics study predicting drug effectiveness; Tr: Time 
of initial research result; Tx: Time to event predicted by the DSS research result; Ty: Time of 
event predicted by the PGxAE results; Tz: Time to event predicted by the PGxEFF result.
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Meeting criteria for when results should be returned: pharmacogenomic versus disease susceptibility study 
results.
Criteria PGxAE DSS
Associated risks are established† +/− +/−
Associated risks are substantial† ++ ++
Medically actionable† +++ +
Useful in reproductive decision-making‡ +/− ++
Where (+) is associated with likelihood of meeting the criterion and where (−) indicates the result is not likely to meet the criterion.
†
National Heart, Lung and Blood Institute 2010 criteria [3].
‡
Incidental Findings Working Group 2008 criteria [5].
DSS: Disease susceptibility study; PGxAE: Pharmacogenomic adverse event study.















Anticipated benefit of returning pharmacogenomic versus disease susceptibility study result.
Characteristic PGxAE result DSS result
Prospect of personal benefit 
(potential for personal meaning)
High, especially if subject associates 
knowledge of result with personal meaning
High, especially if subject associates knowledge of 
result with personal meaning
Prospect of clinical benefit High Low, unless medical intervention
Clinical utility Medically actionable Possible medical intervention
Time to benefit Immediate, early or future Mainly future
DSS: Disease susceptibility study; PGxAE: Pharmacogenomic adverse event study.















Potential harm in returning a false-positive result.
Type of harm PGxAE result DSS result
Clinical/health Not given potentially effective drug
Individual given alternate drug not as effective
Alternate drug may cause other adverse event
Given unnecessary treatment to prevent disease
Treatment may be harmful
Psychosocial Less trust in medical and research enterprise
Less likely to participate in research/clinical testing
Emotional consequences (e.g., anxiety, worry and depression); stigma; 
family discord
Change in career path, in response to anticipating onset of disease
Reproductive Unlikely to affect reproductive decision-making
Other family members may avoid the drug
May affect decision to have children or additional children
Family members may receive unnecessary treatment
Economic Alternate drug may cost more
Insurance may not reimburse
May purchase more insurance
Change career or work, resulting in reduced income
DSS: Disease susceptibility study; PGxAE: Pharmacogenomic adverse event study.















Potential harm in not returning a correct result.
Type of harm PGxAE result DSS result
Clinical/health May develop serious or lethal side effect
May be hospitalized
Cannot ameliorate once lethal event occurs
May develop disease
Will not benefit from prevention available
Psychosocial Less trust in medical and research enterprise
Noncompliant with drug therapy owing to distrust
If disease develops: emotional (e.g., anguish, despair, 
anger, distrust and depression); stigma; change in career 
path
Reproductive Unlikely to affect reproductive decisions
Other family members with variation may be harmed if take drug
May have affected children
Family or children will not receive preventive treatment, 
if available
Economic Hospitalization, insurance, loss of income Medical bills, need additional insurance, less income
DSS: Disease susceptibility study; PGxAE: Pharmacogenomic adverse event study.















Guidance for returning a pharmacogenomics result that predicts adverse events†.
Decision Requirements Examples
Should return





Results that predict serious or life-threatening responses, 
including those likely to: require hospitalization, be disabling or 








Results that predict serious, but not life-threatening responses, 
that are unlikely to require hospitalization, but may result in 







Results that are uncertain or predict mild, temporary responses 
that will resolve in a reasonable time or are treatable by 
medication that neither impose an economic burden nor have 
serious psychological consequences for the individual or family
Do not return SNPs that are not analytically or clinically 
validated
Prediction of mild diarrhea or nausea
†
Guiding principles: first, in general, results should be returned only to research subjects who want to know the findings, unless withholding the 
results will reasonably cause death or irreversible harm to the individual. Second, return of results should be made on a case-by-case basis and must 
consider the clinical, psychosocial, reproductive and economic implications of return of the result to the individual and/or their family. Third, only 
analytically validated results, with a known medical intervention, should be returned. Fourth, the decision to return a pharmacogenomic result that 
predicts adverse events turns on balancing both the risk of harm in withholding an accurate result and the risk of harm in returning a finding of low 
predictive value with the anticipated benefit.
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